BenevolentAI
Drug Discovery
Programmes

The Benevolent Platform empowers our drug discoverers to create a growing pipeline of novel medicines for untreated or poorly treated diseases.

BenevolentAI Drug Programmes

Disease Area
Target ID
Chemistry & Lead Optimisation
Preclinical
Phase 1
Phase 2
Disease Area
Target ID
Chemistry & Lead Optimisation
Preclinical
Phase 1
Phase 2
Atopic Dermatitis
Disease Area
Target ID
Chemistry & Lead Optimisation
Preclinical
Phase 1
Phase 2
Amyotrophic Lateral Sclerosis - Target 1
Disease Area
Target ID
Chemistry & Lead Optimisation
Preclinical
Phase 1
Phase 2
UIcerative Colitis - Target 1
Disease Area
Target ID
Chemistry & Lead Optimisation
Preclinical
Phase 1
Phase 2
UIcerative Colitis - Target 2
Disease Area
Target ID
Chemistry & Lead Optimisation
Preclinical
Phase 1
Phase 2
Amyotrophic Lateral Sclerosis - Target 2
Disease Area
Target ID
Chemistry & Lead Optimisation
Preclinical
Phase 1
Phase 2
Glioblastoma Multiforme - Target 1
Disease Area
Target ID
Chemistry & Lead Optimisation
Preclinical
Phase 1
Phase 2
Chronic Kidney Disease
AstraZeneca
Disease Area
Target ID
Chemistry & Lead Optimisation
Preclinical
Phase 1
Phase 2
Idiopathic Pulmonary Fibrosis
AstraZeneca
Disease Area
Target ID
Chemistry & Lead Optimisation
Preclinical
Phase 1
Phase 2
20+ Early Discovery Programmes
(multiple indications & targets in therapy areas such as Oncology, Immunology, CNS, GI, Metabolic Disorders and Others)
Atopic Dermatitis

“Atopic Dermatitis sadly affects around 230 million people - with prevalence rising. As new ways to treat this disease are desperately needed, we’ve focused on designing a promising new molecule that’s progressed into the clinic as a potential treatment.”

Nikki Robas
Programme Lead
Amyotrophic Lateral Sclerosis

“A progressive degeneration of motor neurons and death occurs within 2 to 3 years of diagnosis in the majority of ALS cases, with available therapies offering little benefit. We continue to identify mechanism-based targets and we are advancing two differentiated small molecule-based ALS therapies in our portfolio, underwriting our commitment to identify disease modifying treatments for this devastating condition”

Peter Cox
VP of Drug Discovery
Glioblastoma Multiforme (GBM)

“Glioblastoma (GBM) is one of the most aggressive and complex brain tumours with a poor prognosis due to its resistance to the current standard of care. Despite intense research and over 1000 clinical trials, GBM is still one of the oncology indications with the highest unmet need. Benevolent uses its AI platform to identify therapeutic targets that would have a disease modifying effect and improve patient outcomes”

Arpita Ray
Senior Principle Scientist
Idiopathic Pulmonary Fibrosis (IPF)

"This exciting collaboration synergises the Benevolent Platform with AstraZeneca’s scientific expertise in IPF, including patient-level data and CRISPR array technology. By adopting a data-driven mechanistic approach to TargetID, we have already generated robust experimental data packages for multiple targets with potential therapeutic utility in IPF"

Chris Tame
Senior Principal Scientist
Chronic Kidney Disease (CKD)

“CKD affects almost 13% of the global population and has limited treatment options to prevent progression to kidney failure. Many interplaying mechanisms make it difficult to find effective treatments. BenevolentAI and AstraZeneca are combining patient-derived data, clinical observations, disease-relevant models and proprietary AI tools to identify better treatments for different patient subgroups.”

Andrea Taddei
Director of Drug Discovery